UA105042C2 - Самомікроемульговувана оральна фармацевтична композиція гідрофільного лікарського засобу і спосіб її одержання - Google Patents

Самомікроемульговувана оральна фармацевтична композиція гідрофільного лікарського засобу і спосіб її одержання

Info

Publication number
UA105042C2
UA105042C2 UAA201113932A UAA201113932A UA105042C2 UA 105042 C2 UA105042 C2 UA 105042C2 UA A201113932 A UAA201113932 A UA A201113932A UA A201113932 A UAA201113932 A UA A201113932A UA 105042 C2 UA105042 C2 UA 105042C2
Authority
UA
Ukraine
Prior art keywords
preparation
pharmaceutical composition
oral pharmaceutical
hydrophilic drug
hydrophilic
Prior art date
Application number
UAA201113932A
Other languages
English (en)
Russian (ru)
Inventor
Чанг-Шан Хсу
Вей-Хуа Хао
Джонг-Джінг Ванг
Цунг-Хсін Лін
Original Assignee
Іннофармакс, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42992661&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA105042(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Іннофармакс, Інк. filed Critical Іннофармакс, Інк.
Publication of UA105042C2 publication Critical patent/UA105042C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Описано самомікроемульговувану оральну фармацевтичну композицію гідрофільного лікарського засобу чи його фармацевтично придатної солі та спосіб їх одержання. Композиція містить гідрофільний лікарський засіб, наприклад бендамустин чи гемцитабін, розчинник, поверхнево-активну речовину та гідрофільний носій, та має добру біодоступність та стабільність. Вказаний гідрофільний носій є сумісним з розчином лікарського засобу та поверхнево-активною речовиною.
UAA201113932A 2009-04-27 2010-04-27 Самомікроемульговувана оральна фармацевтична композиція гідрофільного лікарського засобу і спосіб її одержання UA105042C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17290109P 2009-04-27 2009-04-27
PCT/CN2010/000577 WO2010124525A1 (zh) 2009-04-27 2010-04-27 亲水性药物之自微乳化医药组合物及其制备

Publications (1)

Publication Number Publication Date
UA105042C2 true UA105042C2 (uk) 2014-04-10

Family

ID=42992661

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201113932A UA105042C2 (uk) 2009-04-27 2010-04-27 Самомікроемульговувана оральна фармацевтична композиція гідрофільного лікарського засобу і спосіб її одержання

Country Status (21)

Country Link
US (3) US20100273730A1 (uk)
EP (2) EP3045165B1 (uk)
JP (1) JP5753157B2 (uk)
KR (1) KR101759750B1 (uk)
CN (1) CN102427803B (uk)
AU (1) AU2010242461B2 (uk)
BR (1) BRPI1011764A2 (uk)
CA (1) CA2760039C (uk)
CO (1) CO6470799A2 (uk)
ES (1) ES2831037T3 (uk)
HK (1) HK1165701A1 (uk)
IL (1) IL215988A (uk)
MX (1) MX349014B (uk)
MY (1) MY174001A (uk)
NZ (1) NZ596657A (uk)
RU (1) RU2532362C2 (uk)
SG (1) SG175808A1 (uk)
TW (1) TWI461212B (uk)
UA (1) UA105042C2 (uk)
WO (1) WO2010124525A1 (uk)
ZA (1) ZA201108686B (uk)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3158991B1 (en) 2010-01-28 2021-03-17 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
ES2690257T3 (es) * 2010-06-02 2018-11-20 Astellas Deutschland Gmbh Formas de dosificación oral de bendamustina
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
DK2827862T3 (da) 2012-03-20 2024-02-12 Eagle Pharmaceuticals Inc Formuleringer af bendamustin
WO2013142359A1 (en) 2012-03-20 2013-09-26 Eagle Pharmaceuticals, Inc. Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2015031198A2 (en) 2013-08-27 2015-03-05 Voudouris Vasilios Bendamustine pharmaceutical compositions
IN2014CH00151A (uk) * 2014-01-13 2015-07-17 Hetero Research Foundation
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
MX2017005883A (es) 2014-11-04 2017-11-28 Innopharmax Inc Administracion oral de farmacos inestables o deficientemente absorbidos.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10335405B1 (en) * 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
EP3463298B1 (en) * 2016-06-02 2021-09-01 Innopharmax, Inc. Metronomic oral gemcitabine for cancer therapy
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US20200206139A1 (en) * 2017-09-11 2020-07-02 Board Of Regents, The University Of Texas System Compositions for the improved delivery of drugs
CN110123747A (zh) * 2019-04-26 2019-08-16 嘉兴市爵拓科技有限公司 苯达莫司汀的制剂
KR20220167271A (ko) * 2020-04-13 2022-12-20 유에스 나노 푸드 앤 드럭 인코포레이티드 염기성 화학요법 종양내 주사 제형
CN112006986A (zh) * 2020-08-07 2020-12-01 厦门大学 一种维生素e琥珀酸酯聚乙二醇纳米胶束及其制备方法和应用
CN114397381A (zh) * 2021-12-17 2022-04-26 南京农业大学 一种沼液中阿莫西林的提取及含量检测方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD159289A1 (de) * 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
DE69434626D1 (de) * 1993-11-17 2006-04-20 Athena Neurosciences Inc Transparente flüssigkeit zur verabreichung von verkapselten medikamenten
CA2316539C (en) * 1997-12-26 2008-11-18 Yamanouchi Pharmaceutical Co., Ltd. Sustained-release pharmaceutical composition
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US7217735B1 (en) * 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US7309696B2 (en) * 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
KR100915741B1 (ko) * 2001-06-15 2009-09-04 코너스톤 파마슈티칼스 표적 조직 및 세포를 치료하기에 유용한 나노입자를함유하는 약제학적 및 진단학적 조성물
CA2455288A1 (en) * 2001-06-21 2003-01-03 Pfizer Products Inc. Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
US7053076B2 (en) * 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
DE10306724A1 (de) * 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
DE60318035T2 (de) * 2002-05-03 2008-12-11 Janssen Pharmaceutica N.V. Polymermikroemulsionen
AU2003268087A1 (en) 2002-08-23 2004-03-11 Ian Ma Liposomal gemcitabine compositions for better drug delivery
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
CN1593405A (zh) 2004-07-09 2005-03-16 沈阳药科大学 一种氟康唑液体型组方及其制剂
EP1674081A1 (de) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
CA2640598A1 (en) 2006-02-03 2007-08-09 Noboru Yamazaki Liposome preparation
US20070264349A1 (en) * 2006-03-07 2007-11-15 Novavax, Inc. Nano-structured compositions and methods of making and using the same
KR101545874B1 (ko) * 2007-09-03 2015-08-20 나노테라퓨틱스, 인코포레이티드 난용성 약물의 전달을 위한 입상 조성물

Also Published As

Publication number Publication date
TW201041597A (en) 2010-12-01
RU2532362C2 (ru) 2014-11-10
EP2425818A1 (en) 2012-03-07
TWI461212B (zh) 2014-11-21
EP2425818A4 (en) 2012-10-24
IL215988A0 (en) 2012-01-31
CA2760039C (en) 2017-05-16
MY174001A (en) 2020-03-03
CN102427803A (zh) 2012-04-25
KR20120015330A (ko) 2012-02-21
EP3045165A3 (en) 2016-09-21
JP2012524820A (ja) 2012-10-18
CN102427803B (zh) 2015-06-10
AU2010242461A1 (en) 2011-12-15
EP3045165B1 (en) 2020-09-23
ES2831037T3 (es) 2021-06-07
BRPI1011764A2 (pt) 2016-03-29
NZ596657A (en) 2014-01-31
CA2760039A1 (en) 2010-11-04
KR101759750B1 (ko) 2017-07-31
US20100273730A1 (en) 2010-10-28
AU2010242461B2 (en) 2016-05-19
US20150196537A1 (en) 2015-07-16
EP3045165A2 (en) 2016-07-20
US20190275006A1 (en) 2019-09-12
HK1165701A1 (en) 2012-10-12
ZA201108686B (en) 2012-08-29
JP5753157B2 (ja) 2015-07-22
RU2011148140A (ru) 2013-06-10
SG175808A1 (en) 2011-12-29
MX2011011374A (es) 2012-02-08
WO2010124525A1 (zh) 2010-11-04
CO6470799A2 (es) 2012-06-29
MX349014B (es) 2017-07-06
IL215988A (en) 2016-12-29

Similar Documents

Publication Publication Date Title
UA105042C2 (uk) Самомікроемульговувана оральна фармацевтична композиція гідрофільного лікарського засобу і спосіб її одержання
MY183312A (en) Pharmaceutical formulation
AU2012259422A8 (en) Solid forms of a pharmaceutically active substance
TN2013000253A1 (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
WO2011042918A3 (en) Improved processes for preparing prasugrel and pharmaceutically acceptable salts thereof
MX2009011165A (es) Formulaciones farmaceuticas que contienen derivados del acido lipoico.
WO2009006590A3 (en) Docetaxel process and polymorphs
WO2010092090A3 (en) Novel salts of sitagliptin
MY151986A (en) Adamantyl diamide derivatives and uses of same
BRPI0910758A2 (pt) composição sólida termoestável, composição farmacêutica, processos para a preparação de uma composição sólida termoestável e de uma composição farmacêutica, método para melhorar a biodisponibilidade de um ingrediente farmaceuticamente ativo, e, produto
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2011157722A3 (en) Solid ivabradine-containing composition
WO2010049449A3 (en) Novel salts of sunitinib
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
WO2012140596A8 (en) Glycoside derivatives and uses thereof
TN2012000105A1 (en) Spirolactam derivatives and uses of same
BR112013013903A2 (pt) preparação farmacêutica aquosa estável pronta para uso de cetrorelix para administração parenteral, processo para a fabricação de uma preparação farmacêutica aquosa estável pronta para uso de cetrorelix para uso de cetrorelix para administração parenteral
MX2012007393A (es) Composicion farmaceutica de disolucion rapida comprendiendo lornoxicam.
WO2012108631A3 (en) Pharmaceutical compositions comprising revaprazan-containing nanoparticles and processes for the preparation thereof
WO2013062332A3 (ko) 시링가레시놀을 포함하는 혈관 노화 억제용 조성물
MX2012005596A (es) Derivados de difenil azepano como inhibidores de reabsorcion de monoaminas.
AP2010005204A0 (en) New addition salts of angiotensinconverting enzymeir preparation and pharmaceutical compositions coninhibitors with no donor acids, a process for the taining them
WO2013124832A3 (en) Stabilized controlled-release pharmaceutical composition comprising gliclazide